2024
Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic among Patients with Hematologic Malignancies in the United States
Neparidze N, W. Lau K, Wang X, Huntington S, Jamy O, S. Calip G, Shah H, M. Stephens D, Miksad R, Parikh R, Takvorian S, Goyal G, Seymour E. Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic among Patients with Hematologic Malignancies in the United States. Medical Research Archives 2024, 12 DOI: 10.18103/mra.v12i2.5164.Peer-Reviewed Original ResearchAcute myelogenous leukemiaMantle cell lymphomaChronic lymphocytic leukemiaDiffuse large B-cell lymphomaFollicular lymphomaMultiple myelomaWhite patientsBlack patientsCell lymphomaHematologic malignanciesLymphocytic leukemiaTreatment categoriesElectronic health record (EHR)-derived de-identified databaseDiagnosis of acute myelogenous leukemiaLarge B-cell lymphomaTelemedicine uptakeActive patientsLines of therapyB-cell lymphomaMonthly visit ratesMyeloma patientsVisit ratesAnalyzed patientsMyelogenous leukemiaLymphoma
2022
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy
Perl A, Larson R, Podoltsev N, Strickland S, Wang E, Atallah E, Schiller G, Martinelli G, Neubauer A, Sierra J, Montesinos P, Recher C, Yoon S, Maeda Y, Hosono N, Onozawa M, Kato T, Kim H, Hasabou N, Nuthethi R, Tiu R, Levis M. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy. Transplantation And Cellular Therapy 2022, 29: 265.e1-265.e10. PMID: 36526260, PMCID: PMC10189888, DOI: 10.1016/j.jtct.2022.12.006.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationAcute myelogenous leukemiaPost-transplantation maintenance therapyLower relapse rateAdverse eventsADMIRAL trialMaintenance therapyPost-transplantation survivalGilteritinib armRelapse rateSalvage chemotherapyMyelogenous leukemiaRefractory acute myelogenous leukemiaTreatment-emergent adverse eventsFLT3 internal tandem duplication (ITD) mutationsCommon adverse eventsComposite complete remissionGlobal phase 3Incidence of gradePost-transplantation complicationsTransplantation-eligible patientsAlanine aminotransferase levelsHigher remission ratesOverall survival rateSurvival of patientsChapter 9 Vascular disorders epidemiology
Kurz S, Rogers L. Chapter 9 Vascular disorders epidemiology. 2022, 81-86. DOI: 10.1016/b978-0-12-822835-7.00060-3.Peer-Reviewed Original ResearchCancer patientsOpportunistic fungal infectionBone marrow transplantationAcute myelogenous leukemiaCerebral venous thrombosisCause of ischemic strokeAcute promyelocytic leukemiaMarrow transplantationMyelogenous leukemiaHematological tumorsVenous thrombosisMetastatic cancerFungal infectionsHealthy controlsTumor treatmentCerebral infarctionTumorAntineoplastic drugsBrain tumorsSubdural spaceRelative riskPromyelocytic leukemiaCancerIntraparenchymal haemorrhageLeukemia
2020
210 Regulation of TIM-3 by phosphatidylserine
Smith C, Li A, Krishnamurthy N, Lemmon M. 210 Regulation of TIM-3 by phosphatidylserine. Journal For ImmunoTherapy Of Cancer 2020, 8: a229-a229. DOI: 10.1136/jitc-2020-sitc2020.0210.Peer-Reviewed Original ResearchTim-3-expressing cellsTim-3 antibodyTim-3 functionTim-3Exhausted T cellsT cell signalingPD-1Receptor expressionT cellsTIM-1Tumor antigen-specific CD8Role of PST cell exhaustion phenotypeTim-3 receptorAntigen-specific CD8PD-1-mediated inhibitionPD-1 expressionImmune checkpoint blockadeMajority of patientsCheckpoint blockade therapyT cell dysfunctionImmune checkpoint receptorsAcute myelogenous leukemiaApoptotic cellsNew therapeutic targetsRisk associated alterations in marrow T cells in pediatric leukemia
Bailur JK, McCachren SS, Pendleton K, Vasquez JC, Lim H, Duffy A, Doxie D, Kaushal A, Foster C, DeRyckere D, Castellino S, Kemp ML, Qiu P, Dhodapkar M, Dhodapkar K. Risk associated alterations in marrow T cells in pediatric leukemia. JCI Insight 2020, 5: e140179. PMID: 32692727, PMCID: PMC7455136, DOI: 10.1172/jci.insight.140179.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBone MarrowCase-Control StudiesChildChild, PreschoolFemaleGene Expression ProfilingHumansInfantKiller Cells, NaturalLeukemia, Myeloid, AcuteMalePrecursor Cell Lymphoblastic Leukemia-LymphomaReproducibility of ResultsRisk FactorsSingle-Cell AnalysisT-LymphocytesTumor MicroenvironmentConceptsAcute lymphoblastic leukemiaNaive T cellsT cellsDisease riskChildhood leukemiaLymphoblastic leukemiaStem-like memory T cellsTerminal effector T cellsB-cell acute lymphoblastic leukemiaChronic immune activationCell acute lymphoblastic leukemiaEffector T cellsMarrow T cellsMemory T cellsAcute myelogenous leukemiaEvidence of dysfunctionStem-like genesImmune signaturesNK cellsClinical featuresImmune environmentImmune landscapeImmune therapyImmune activationImmune microenvironment
2019
Lobular neutrophilic panniculitis associated with DNA methyltransferase inhibitors in the treatment of myeloid disease
Coleman E, Panse G, Cowper S, Prebet T, Gore S, Leventhal J. Lobular neutrophilic panniculitis associated with DNA methyltransferase inhibitors in the treatment of myeloid disease. Journal Of Cutaneous Pathology 2019, 46: 930-934. PMID: 31254406, DOI: 10.1111/cup.13537.Peer-Reviewed Original ResearchConceptsLobular neutrophilic panniculitisNeutrophilic panniculitisDNA methyltransferase inhibitorNeutrophilic eccrine hidradenitisInjection site reactionsAcute myelogenous leukemiaMethyltransferase inhibitorNeutrophilic dermatosisSweet's syndromeMaculopapular eruptionCutaneous toxicityHistopathologic characteristicsSite reactionsNext-generation agentsDifferential diagnosisMyelogenous leukemiaTreatment considerationsMyeloid diseasesPanniculitisTreatmentInhibitorsFirst reportGangrenosumHidradenitisEcchymosis
2016
Aplastic Anemia and MDS International Foundation (AAMDSIF): Bone marrow failure disease scientific symposium 2016
Zeidan AM, Battiwalla M, Berlyne D, Winkler T. Aplastic Anemia and MDS International Foundation (AAMDSIF): Bone marrow failure disease scientific symposium 2016. Leukemia Research 2016, 53: 8-12. PMID: 27923195, PMCID: PMC7731993, DOI: 10.1016/j.leukres.2016.11.011.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBone marrow failure syndromesMDS International FoundationAplastic anemiaPeripheral blood cytopeniasAcute myelogenous leukemiaMarrow failure syndromesBlood cytopeniasCommon manifestationIneffective hematopoiesisMyelogenous leukemiaFailure syndromeClinical implicationsHematopoietic stem cell compartmentStem cell compartmentPatientsAnemiaCell compartmentFamily membersIndependent nonprofit organizationInternational FoundationCytopeniasSyndromePathogenesisLeukemia
2015
Characteristics of Bacteremia in Pediatric Oncology Patients Based on Pathogen Classification as Associated with the Gastrointestinal Mucosa or Skin
Flagg A, Worley S, Foster CB. Characteristics of Bacteremia in Pediatric Oncology Patients Based on Pathogen Classification as Associated with the Gastrointestinal Mucosa or Skin. Infection Control And Hospital Epidemiology 2015, 36: 730-733. PMID: 25773335, DOI: 10.1017/ice.2015.48.Peer-Reviewed Original ResearchConceptsGastrointestinal mucosaCharacteristics of bacteremiaEnteric Gram-negativesBlood stream infectionsPediatric oncology patientsAcute myelogenous leukemiaCentral cathetersOncology patientsOral floraMyelogenous leukemiaSkin organismsBacteremiaPatientsMucosaGram-negativesMucositisCatheterLeukemiaInfection
2011
Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis
Holkova B, Tombes M, Shrader E, Cooke S, Wan W, Sankala H, Kmieciak M, Roberts J, Garcia-Manero G, Grant S. Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis. Blood 2011, 118: 2598. DOI: 10.1182/blood.v118.21.2598.2598.Peer-Reviewed Original ResearchRefractory acute leukemiaMyelodysplastic syndromeAcute leukemiaChronic myelogenous leukemiaMyelogenous leukemiaI trialCML-BCBlast crisisDay 1ECOG performance score 0Hematopoietic stem cell transplantationPerformance score 0Phase II dosesRecent preclinical findingsPeripheral sensory neuropathySerious adverse eventsMinute intravenous infusionPhase I trialPhase II evaluationPrimary acute myelogenous leukemiaSchedule of administrationStem cell transplantationBiphenotypic acute leukemiaCombination of bortezomibAcute myelogenous leukemia
1990
RAS gene activation in acute myelogenous leukemia: Analysis by in vitro amplification and dna base sequence determination
Mane S, Meltzer S, Gutheil J, Kapil V, Lee E, Needleman S. RAS gene activation in acute myelogenous leukemia: Analysis by in vitro amplification and dna base sequence determination. Genes Chromosomes And Cancer 1990, 2: 71-77. PMID: 2278967, DOI: 10.1002/gcc.2870020113.Peer-Reviewed Original ResearchMeSH KeywordsBase SequenceCohort StudiesDNA Mutational AnalysisDNA, NeoplasmExonsGene Expression Regulation, NeoplasticGenes, rasHumansIatrogenic DiseaseLeukemia, Myeloid, AcuteMolecular Sequence DataPolymerase Chain ReactionProspective StudiesProto-Oncogene Proteins p21(ras)Transcriptional ActivationConceptsAcute myeloid leukemia patientsMaryland Cancer CenterMyeloid leukemia patientsAcute myelogenous leukemiaRAS gene activationProspective cohortCancer CenterLeukemia patientsPrecise prevalenceMyelogenous leukemiaNRAS mutationsRas activationRas mutationsGene point mutationsBiologic parametersLarger studyHuman cancersPatientsAMLProtooncogene activationExon mutationsActivationCell DNAMutationsPoint mutations
1989
c-myc amplification coexistent with activating N-ras point mutation in the biphenotypic leukemic cell line RED-3.
Mallet M, Mane S, Meltzer S, Needleman S. c-myc amplification coexistent with activating N-ras point mutation in the biphenotypic leukemic cell line RED-3. Leukemia 1989, 3: 511-5. PMID: 2659902.Peer-Reviewed Original ResearchConceptsCell linesMYC activationAcute myelogenous leukemiaN-ras point mutationsActivating point mutationC-MycN-rasAML patientsAcute leukemiaHL-60AML cellsMyelogenous leukemiaAggressive acute leukemiasLineage infidelityHuman tumorsDerivative cell linesPoint mutationsPatientsLeukemiaActivationSmall proportionCellsRed 3Protooncogene cMalignancy
1985
Low‐dose cytosine arabinoside in the myelodysplastic syndromes and acute myelogenous leukemia
Roberts JD, Ershler WB, Tindle BH, Stewart JA. Low‐dose cytosine arabinoside in the myelodysplastic syndromes and acute myelogenous leukemia. Cancer 1985, 56: 1001-1005. PMID: 3860278, DOI: 10.1002/1097-0142(19850901)56:5<1001::aid-cncr2820560504>3.0.co;2-p.Peer-Reviewed Original ResearchConceptsLow-dose cytosineAcute myelogenous leukemiaMyelodysplastic syndromeMyelogenous leukemiaTransient hematologic toxicityPeripheral blood countsAppropriate clinical roleTransfusion requirementsHematologic toxicityPartial responseDecreased incidenceBlood countClinical roleLow dosagePatientsSyndromeLeukemiaInfectionIncidenceCessation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply